Harbinger Health recently announced a new partnership with Memorial Sloan Kettering Cancer Center to accelerate the validation of its AI-supported blood test for early-stage cancer detection and presented encouraging data at the American Association for Cancer Research (AACR) conference in San Diego this week.
The liquid biopsy company said it plans to leverage MSK’s cancer center and academic institution to validate its assay in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?